Riverhead Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Riverhead Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-7,600	Closed	-$253K	–	1546
2017 Q2	$253K	Hold	7,600	–	–	0.01%	827
2017 Q1	$244K	Hold	7,600	–	–	0.01%	721
2016 Q4	$275K	Hold	7,600	–	–	0.02%	648
2016 Q3	$350K	Sell	7,600 -9,065	-54%	-$473K	0.02%	546
2016 Q2	$837K	Sell	16,665 -12,878	-44%	-$686K	0.03%	477
2016 Q1	$1.58M	Sell	29,543 -757	-2%	-$44.4K	0.02%	579
2015 Q4	$1.99M	Hold	30,300	–	–	0.03%	522
2015 Q3	$1.71M	Hold	30,300	–	–	0.03%	500
2015 Q2	$1.79M	Hold	30,300	–	–	0.03%	506
2015 Q1	$1.89M	Hold	30,300	–	–	0.03%	498
2014 Q4	$1.74M	Hold	30,300	–	–	0.03%	507
2014 Q3	$1.63M	Hold	30,300	–	–	0.03%	478
2014 Q2	$1.59M	Hold	30,300	–	–	0.03%	476
2014 Q1	$1.6M	Buy	+30,300	New	+$1.4M	0.04%	465

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Riverhead Capital Management's TEVA Position: Q3 2017 in Review

Riverhead Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 7,600 shares — an estimated $253K sold.

Riverhead Capital Management first reported a position in TEVA in Q1 2014 and held it in 14 quarters. The position peaked at $1.99M in Q4 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Riverhead Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Riverhead Capital Management sold 7,600 Teva Pharmaceuticals shares in Q3 2017, an estimated $253K.
Riverhead Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 14 quarters.
Riverhead Capital Management's Teva Pharmaceuticals position peaked at $1.99M in Q4 2015.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Riverhead Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.